ABAlessandro Buonomo

Alessandro Buonomo

*This is an algorithmically generated author record based on publicly available information.

Alessandro Buonomo has a total of 84 co-authors. Here are the top co-authors by number of shared publications:

  • Arianna Aruanno

    UOSD Allergy and Clinical Immunology Unit, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, 00168 Rome, Italy

    12 shared publications
  • Angela Rizzi

    UOSD Allergy and Clinical Immunology Unit, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, 00168 Rome, Italy

    8 shared publications
  • David Longhino

    Scuola di Specializzazione in Allergologia e Immunologia Clinica Università Cattolica del Sacro Cuore, 00168 Roma, Italy

    6 shared publications
  • Eleonora Nucera

    Allergy Unit, Università Cattolica del Sacro Cuore, Policlinico A. Gemelli, Rome, Italy

    6 shared publications
  • Antonio Gasbarrini

    Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, 00168 Rome, Italy

    4 shared publications
  • Domenico Schiavino

    Allergy Unit, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy

    4 shared publications

Latest Publications

  • Open Access

    IgE-mediated allergic reactions to ocrelizumab in multiple sclerosis: A retrospective cohort study

    by Assunta Bianco, Arianna Aruanno, Matteo Lucchini, Alessandra Cicia, David Longhino, Marco Bisurgi, Francesca Colò, Vincenzo Carlomagno, Angela Rizzi, Alessandro Buonomo, et al.

  • Open Access

    Biomarker-Associated Remission After Switching to Dupilumab in Severe Asthma Following Failure of Prior Biologics

    by Fabio Romano Selvi, David Longhino, Gabriele Lucca, Ilaria Baglivo, Maria Antonietta Zavarella, Chiara Laface, Laura Bruno, Arianna Delfino Spiga, Sara Gamberale, Ludovica Fabbroni, et al.

    Background/Objectives: Severe asthma remains difficult to treat, even with the range of biologics we now have that target type 2 inflammation. Some patients do not respond well enough to the first biologic they try, which raises the question of whether switching to another option can help. In this study, we looked at how patients who had unsatisfactory therapeutic outcomes on other biologics responded—both clinically and at the biomarker level—after switching to dupilumab. Methods: We reviewed data from the Allergy and Clinical Immunology Unit of Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy, between January and June 2025. The study included fifteen adults with uncontrolled severe asthma who had previously been treated for at least six months with benralizumab, omalizumab, or mepolizumab before switching to dupilumab. We evaluated demographic, clinical and laboratory data. Lung function (Forced Expiratory Volume in 1 s (FEV1)), blood eosinophils, total and specific IgE to staphylococcal enterotoxins, eosinophil cationic protein (ECP), free light chains (FLC), and FeNO were assessed at the time of the switch and again after 12 months. Comparisons were made using paired tests, and a p-value < 0.05 was considered statistically significant. Results: After a year on dupilumab, we saw clear improvements: mean FEV1 went up by about 10.8% predicted (p = 0.002), FeNO dropped by an average of 22 ppb (p = 0.005), blood eosinophils fell by roughly 400 cells/µL (p = 0.003), and ECP levels decreased by 13 µg/L (p = 0.009). Kappa FLCs also showed a significant drop (p = 0.04). Clinically, 40% of patients met criteria for a meaningful response, and 20% achieved complete remission. Dependence on oral corticosteroids was notably reduced. Baseline levels of eosinophils, ECP, IgE, and FLCs correlated with response to treatment. Conclusions: Our study, despite the small sample size, highlights that in patients with severe asthma who do not show a good response to their first biologic, switching to dupilumab can lead to significant improvements. Markers of type 2 inflammation at baseline might help predict who benefits most. Larger, multi-center, prospective studies are needed to confirm these results.


  • Open Access

    Biomarker-Associated Remission with Anti-IL-4R/IL-13 Therapy After Failure of Prior Biologics in Severe Asthma

    by Fabio Romano Selvi, David Longhino, Gabriele Lucca, Ilaria Baglivo, Maria Antonietta Zavarella, Chiara Laface, Laura Bruno, Arianna Delfino Spiga, Sara Gamberale, Ludovica Fabbroni, et al.

    Background/Objectives Severe asthma remains difficult to treat, even with the range of biologics we now have that target type 2 inflammation. Some patients do not respond well enough to the first biologic they try, which raises the question of whether switching to another option can help. In this study, we looked at how patients who had unsatisfactory therapeutic outcomes on other biologics responded—both clinically and at the biomarker level—after switching to dupilumab. Methods We reviewed data from the Allergy and Clinical Immunology Unit of Fondazione Policlinico Universitario A. Gemelli-IRCCS between January and June 2025. The study included fifteen adults with uncontrolled severe asthma who had previously been treated for at least six months with benralizumab, omalizumab, or mepolizumab before switching to dupilumab. We assessed lung function (FEV₁), blood eosinophils, IgE, eosinophil cationic protein (ECP), free light chains (FLC), and FeNO at the time of the switch and again after 12 months. Statistical comparisons were made using paired tests, with significance set at p < 0.05. Results After a year on dupilumab, we saw clear improvements: mean FEV₁ went up by about 10.8% predicted (p = 0.002), FeNO dropped by an average of 22 ppb (p = 0.005), blood eosinophils fell by roughly 400 cells/µL (p = 0.003), and ECP levels decreased by 13 µg/L (p = 0.009). Kappa FLCs also showed a significant drop (p = 0.04). Clinically, 40% of patients met criteria for a meaningful response, and 20% achieved complete remission. Dependence on oral corticosteroids was notably reduced. Baseline levels of eosinophils, ECP, IgE, and FLCs correlated with response to treatment. Conclusions For patients with severe asthma who do not show a good response to their first biologic, switching to dupilumab can lead to significant clinical and biomarker improvements. Markers of type 2 inflammation at baseline might help predict who benefits most. Larger, prospective studies are needed to confirm these results.

  • Open Access

    Safety and Tolerability of a 3‐h Build‐Up Phase With Hymenoptera Venom Depot Extracts: Preliminary Results

    by Alessandro Buonomo, Roberta Massaro, David Longhino, Arianna Aruanno, Cristiano Caruso, Eleonora Nucera, Antonio Gasbarrini


  • Open Access

    Safety and tolerability of a 3-hour build-up phase with Hymenoptera venom depot extracts: preliminary results

    by Buonomo Alessandro, Roberta Massaro, David Longhino, Aruanno A, Cristiano Caruso, Eleonora Nucera, Antonio Gasbarrini

  • Open Access

    Anaphylaxis after SonoVue: A Case Report and a Literature Review

    by David Longhino, Alessandro Buonomo, Maria Assunta Zocco, Maria Elena Ainora, Giorgio Esposto, Irene Mignini, Lucia Cerrito, Francesca Romana Ponziani, Antonio Gasbarrini, Eleonora Nucera, et al.

    SonoVue (Bracco, Milan, Italy) is a drug used in ultrasonography for the purpose of increasing the echogenicity of blood or fluids by improving the signal-to-noise ratio. Background/Objectives/Methods: We described a case of anaphylaxis due to SonoVue and performed a literature review. Results and Conclusions: We reported a case of anaphylaxis secondary to the administration of SonoVue and described all the 13 literature cases. Given its widespread use and the potentially dangerous nature of the reactions it can cause, it is advisable to know how to promptly recognize fatal reactions.


  • Perioperative anaphylaxis to chlorhexidine: Crucial role of in-vitro testing

    by Alessandro Buonomo, Arianna Aruanno, Valter Perilli, Angela Rizzi, Manuela Ferraironi, Eleonora Nucera

    Background: Chlorhexidine is a synthetic biguanide with a broad antibacterial activity and has become an important cause of perioperative anaphylaxis. Objective: Reactions due to chlorhexidine allergy are usually IgE-mediated. The aim of this report is to demonstrate utility of laboratory in -vitro testing for diagnosis. Methods: We report the case of a 36 -year old man who experienced severe anaphylaxis during general anesthesia. He underwent skin tests, specific detection of specific IgE to chlorhexidine and basophil activation test (BAT). Results: Skin tests gave false positive results due to dermographism. So, on the basis of a clinical reaction to chlorhexidine and positive tests for IgE to chlorexidine and BAT, we assessed the diagnosis of chlorhexidine allergy. Conclusion: Physicians should be aware of the role of chlorhexidine in the etiology of perioperative anaphylaxis. In vitro testing such specific IgE and BAT are useful in patient with suspected chlorexidine allergy and limitation to perform skin tests.


  • Open Access

    A Modified Basophil Activation Test for the Clinical Management of Immediate Hypersensitivity Reactions to Paclitaxel: A Proof-of-Concept Study

    by Marilena La Sorda, Marco Fossati, Rosalia Graffeo, Manuela Ferraironi, Maria Cristina De Rosa, Alexia Buzzonetti, Benedetta Righino, Nicole Zampetti, Andrea Fattorossi, Eleonora Nucera, et al.

    Immediate hypersensitivity reactions (iHSRs) to taxanes are observed in 6% and 4% of gynecologic and breast cancer patients, respectively. Drug desensitization is the only option, as no comparable alternative therapy is available. Surfactants in the taxane formulation have been implicated in the immunopathogenesis of iHSRs, although sporadic skin test (ST) positivity and iHSRs to nab-paclitaxel have suggested the involvement of the taxane moiety and/or IgE-mediated pathomechanisms. In vitro diagnostic tests might offer insights into mechanisms underlying iHSRs to taxanes. The aim of the present study was to address this unmet need by developing a novel basophil activation test (BAT). The study included patients (n = 31) undergoing paclitaxel/carboplatin therapy. Seventeen patients presented with iHSRs to paclitaxel (iHSR-Taxpos), and eleven were tolerant (iHSR-Taxneg). Fourteen patients presented with iHSRs to carboplatin (iHSR-Plpos), and fourteen were tolerant (iHSR-Plneg). The BAT median stimulation index (SI) values were 1.563 (range, 0.02–4.11; n = 11) and −0.28 (range −4.88–0.07, n = 11) in iHSR-Taxpos and iHSR-Taxneg, respectively. The BAT median SI values were 4.45 (range, 0.1–26.7; n = 14) and 0 (range, −0.51–1.65; n = 12) in iHSR-Plpos and iHSR-Plneg, respectively. SI levels were not associated with iHSR severity grading. Comparing BAT results in iHSR-Taxpos and iHSR-Taxneg showed the area under the receiver operator characteristic (ROC) curve to be 0.9752 (p = 0.0002). The cutoff calculated by the maximized likelihood ratio identified 90.91% of iHSR-Taxpos patients and 90.91% of iHSR-Taxneg patients. Comparing BAT results for iHSR-Plpos and iHSR-Plneg showed the area under the ROC curve to be 0.9286 (p = 0.0002). The cutoff calculated by the maximized likelihood ratio identified 78.57% of iHSR-Plpos patients and 91.67% of iHSR-Plneg patients. Most iHSR-Taxpos patients for which ST was available (10/11) scored ST-negative and BAT-positive, whereas most iHSR-Plpos patients for which ST was available (14/14) scored both BAT- and ST-positive. This suggested the intervention of non-IgE-mediated mechanisms in iHSR-Taxpos patients. Consistent with this view, an in silico molecular docking analysis predicted the high affinity of paclitaxel to the degranulation-competent MRGPRX2 receptor. This hypothesis warrants further in vitro investigations. In conclusion, the present study provides preliminary proof-of-concept evidence that this novel BAT has potential utility in understanding mechanisms underlying iHSRs to taxanes.


  • Open Access

    Epinephrine Auto-Injector Prescription and Use: A Retrospective Analysis and Clinical Risk Assessment of Adult Patients Sensitized to Lipid Transfer Protein

    by Sara Urbani, Arianna Aruanno, Antonio Gasbarrini, Alessandro Buonomo, Rossana Moroni, Caterina Sarnari, Angela Rizzi, Eleonora Nucera

    Lipid transfer proteins (LTPs) are widely widespread plant food allergens which represents the main cause of food allergy in adults living in the Mediterranean basin. The purpose of this study was to investigate in LTP patients the actual use of prescribed epinephrine auto-injector and appropriateness of its prescription. In addition, we investigated in these patients: (1) occurrence of new food reaction in the following three years after to diagnosis; (2) need and number of access to emergency services; (3) presence of possible predictive factors to further food reactions. One-hundred sixty-five adult patients sensitized to LTPs have been included. During follow-up, we recorded 68 further reactions, most of them (77.9%) characterized by local symptoms; rarely the patients required an emergency-department visits (16.1%) and only one patient (1.7%) used the epinephrine auto-injector. The patients with a previous history of anaphylaxis at baseline turned back to access to emergency services also during the follow-up (p = 0.006). The majority of patients with recorded systemic reactions (p = 0.004) and treated in an emergency room (p = 0.028) did not have any co-factor-enhanced at diagnosis. We noted an association between platanus pollen sensitization and severity of further reactions during the follow-up (p = 0.026). Epinephrine auto-injector were prescribed to 108/165 patients (65.5%) with an over-prescription rate of 25%. The unforeseeable clinical presentation of LTP allergic reactions and the eventual role played by the cofactor make necessary schedule a follow-up to monitor the patients over time and to assess the actual use of epinephrine auto injectors prescribed.